Esam Elshimi1, Mostafa Abdel-Samed Mostafa Sakr2, Wesam Saber Morad3, Lobna Mohammad2. 1. Hepatology Department, National Liver Institute, Menoufia University, Shebin Al-Kom, Egypt. 2. Genetic Engineering Institute, Sadat University, Sadat, Egypt. 3. Community Department, National Liver Institute, Menoufia University, Shebin Al-Kom, Egypt.
Abstract
BACKGROUND AND AIMS: Matrix metalloproteinase-12 (MMP-12) is involved in tumor invasiveness and metastasis and significantly overexpressed in hepatocellular carcinoma (HCC) tissues. We aimed to investigate the diagnostic and prognostic value of blood mRNA MMP-12 overexpression in patients with HCC. PATIENTS AND METHODS: From January 2017 to June 2017, 100 patients with HCC (HCV-related cirrhosis) and 100 patients with HCV-related cirrhosis (without HCC) were included in this study. All patients were subjected to triphasic CT abdomen when indicated, liver profile, alpha-fetoprotein (AFP), and molecular characterization of metalloproteinase-12 expression. RESULTS: There were no statistically significant differences between both groups regarding CBC parameters and liver profile (p value > 0.05). There was a statistically significant difference between patients with and without HCC regarding blood mRNA MMP-12 overexpression (p value < 0.01), blood mRNA MMP-12, and/or AFP (sensitivity 84.0%, specificity 60.0%, PPV 51.2%, and NPP 88.2%). The accuracy of mRNA MMP-12 and/or AFP in detection of HCC was 68.0%. CONCLUSION: Blood mRNA MMP-12 has a good sensitivity and a bad specificity but is accurate in HCC diagnosis. Adding blood mRNA MMP-12 to AFP optimizes the current screening program to improve early diagnosis of HCC and hence better prognosis.
BACKGROUND AND AIMS: Matrix metalloproteinase-12 (MMP-12) is involved in tumor invasiveness and metastasis and significantly overexpressed in hepatocellular carcinoma (HCC) tissues. We aimed to investigate the diagnostic and prognostic value of blood mRNA MMP-12 overexpression in patients with HCC. PATIENTS AND METHODS: From January 2017 to June 2017, 100 patients with HCC (HCV-related cirrhosis) and 100 patients with HCV-related cirrhosis (without HCC) were included in this study. All patients were subjected to triphasic CT abdomen when indicated, liver profile, alpha-fetoprotein (AFP), and molecular characterization of metalloproteinase-12 expression. RESULTS: There were no statistically significant differences between both groups regarding CBC parameters and liver profile (p value > 0.05). There was a statistically significant difference between patients with and without HCC regarding blood mRNA MMP-12 overexpression (p value < 0.01), blood mRNA MMP-12, and/or AFP (sensitivity 84.0%, specificity 60.0%, PPV 51.2%, and NPP 88.2%). The accuracy of mRNA MMP-12 and/or AFP in detection of HCC was 68.0%. CONCLUSION: Blood mRNA MMP-12 has a good sensitivity and a bad specificity but is accurate in HCC diagnosis. Adding blood mRNA MMP-12 to AFP optimizes the current screening program to improve early diagnosis of HCC and hence better prognosis.
Authors: J Bruix; M Sherman; J M Llovet; M Beaugrand; R Lencioni; A K Burroughs; E Christensen; L Pagliaro; M Colombo; J Rodés Journal: J Hepatol Date: 2001-09 Impact factor: 25.083
Authors: A Karim Kader; Lina Shao; Colin P Dinney; Matthew B Schabath; Yunfei Wang; Jun Liu; Jian Gu; H Barton Grossman; Xifeng Wu Journal: Cancer Res Date: 2006-12-15 Impact factor: 12.701
Authors: H Hirte; R Goel; P Major; L Seymour; S Huan; D Stewart; J Yau; A Arnold; S Holohan; B Waterfield; S Bates; K Bennett; W Walsh; I Elias Journal: Ann Oncol Date: 2000-12 Impact factor: 32.976
Authors: M Abdel-Wahab; A A el-Enein; M Abou-Zeid; A el-Fiky; T Abdallah; M Fawzy; A Fouad; A Sultan; O Fathy; G el-Ebidy; N elghawalby; F Ezzat Journal: Hepatogastroenterology Date: 2000 May-Jun
Authors: Li Su; Wei Zhou; Kofi Asomaning; Xihong Lin; John C Wain; Thomas J Lynch; Geoffrey Liu; David C Christiani Journal: Carcinogenesis Date: 2005-11-25 Impact factor: 4.944
Authors: M J Moore; J Hamm; J Dancey; P D Eisenberg; M Dagenais; A Fields; K Hagan; B Greenberg; B Colwell; B Zee; D Tu; J Ottaway; R Humphrey; L Seymour Journal: J Clin Oncol Date: 2003-09-01 Impact factor: 44.544